Nasal blockage is a common complaint in Family Practice. Decongestive nosedrops are frequently employed therapeutic measures. Due to a considerable risk of abuse and side effects, alternatives are wanted. The purpose of this study was to elucidate to what extent ENDS might represent an alternative to decongestive nose sprays (DNS). The effects of DNS (xylometazolin) and ENDS (BreatheRight) on subjective and objective nasal blockage were compared in 89 patients. Main outcome measures were recordings of nasal symptom scores on visual analogue scales (VAS), minimal cross-sectional areas (MCA) and nasal cavity volumes (NCV) as measured by acoustic rhinometry (AR), and peak nasal inspiratory flow (PNIF). ENDS significantly increased the MCA and the NCV in the anterior 0.0-3.0 cm of the nose compared to DNS, but had no effect on MCA from 3.0 to 5.4 cm behind the nostrils. In contrast to DNS, ENDS had no effect on the posterior NCV. ENDS and DNS gave comparable increase in nasal inspiratory flow as measured by PNIF, and in the subject's own experience of nasal obstruction. ENDS may represent an alternative to DNS as a measure against nasal blockage.